Update shared on30 Jul 2025
Fair value Increased 23%The consensus analyst price target for Insight Molecular Diagnostics has increased to $5.42, primarily reflecting improved revenue growth forecasts and a rising future P/E multiple.
What's in the News
- The company changed its name from Oncocyte Corporation to Insight Molecular Diagnostics Inc. and updated its bylaws to reflect the new name.
- Insight Molecular Diagnostics was dropped from several Russell Growth Indexes and added to corresponding Russell Value Indexes, indicating a classification shift from growth to value.
- The company announced positive study results for its GraftAssureIQ research-use-only test kit, showing equivalent performance to a competing product in measuring donor-derived cell-free DNA, and is developing GraftAssureDx for future clinical use.
- CMS increased the reimbursement rate for the company’s GraftAssureCore transplant rejection test to $2,753 per result, improving expected economics and setting a benchmark for potential future FDA-cleared kits.
- The company reported progress on clinical trial site activation for GraftAssureDx, with major U.S. transplant centers expected to participate and aims for FDA submission by year-end.
Valuation Changes
Summary of Valuation Changes for Insight Molecular Diagnostics
- The Consensus Analyst Price Target has significantly risen from $4.42 to $5.42.
- The Future P/E for Insight Molecular Diagnostics has significantly risen from 179.36x to 214.35x.
- The Consensus Revenue Growth forecasts for Insight Molecular Diagnostics has risen from 29.7% per annum to 32.1% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.